Retatrutide has an expanding clinical-development record as well as laboratory pharmacology studies. Its name now appears in papers, conference announcements and research catalogues. Those appearances do not carry the same evidential meaning. This guide identifies the molecule and gives a dated route through selected records, with the status of each source made explicit.
Understand what triple agonist describes
Urva and colleagues describe LY3437943 as a single 39-residue peptide conjugated to a C20 fatty-diacid group. The lipid modification is part of the molecular description, not a separate peptide in a blend.Urva and colleagues — LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes (opens in a new tab)
Coskun and colleagues’ 2022 discovery paper investigates activity at GIP, GLP-1 and glucagon receptors. Its laboratory findings describe differing activity across those receptor systems.Coskun and colleagues — LY3437943: From discovery to clinical proof of concept (opens in a new tab)
| Field | Meaning in this record |
|---|---|
| Retatrutide / LY3437943 | Two names for the investigated molecule |
| Single modified peptide | One molecular agent with a lipid conjugate |
| Triple receptor agonism | Activity investigated at three receptor targets |
The word triple therefore does not mean a mixture of three medicines, or prove an equal contribution from each receptor to every observed outcome. Molecular identity and receptor activity should remain separate entries in a research summary.
Read the published obesity trial as a defined comparison
Jastreboff and colleagues’ 2023 phase 2 paper reports a randomised, double-blind, placebo-controlled trial involving 338 adults. The primary weight-change endpoint was at 24 weeks, with further outcomes at 48 weeks.Jastreboff and colleagues — Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (opens in a new tab)
The study reported larger average weight reductions with retatrutide than placebo. It also reported adverse events, most commonly gastrointestinal, and treatment discontinuations related to adverse events.Jastreboff and colleagues — Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (opens in a new tab)
A research summary should retain both outcome and tolerability information. Selecting only the largest reported weight-change figure removes information needed to judge the comparison.
The different follow-up points should not be silently combined. A later secondary measurement and an earlier primary endpoint have different roles in the study’s planned analysis.
These are results from a clinical trial of a specified investigational preparation. A research catalogue sharing the compound name is not evidence that its supplied material was included in that trial.
Date the newer phase 3 information
On 23 July 2026, Lilly announced positive topline results from the TRIUMPH-2 and TRIUMPH-3 phase 3 trials. The release continued to describe retatrutide as investigational and reported planned regulatory submissions.Lilly — Retatrutide results in two additional phase 3 obesity trials, 23 July 2026 (opens in a new tab)
A 15 September 2026 announcement listed forthcoming presentations at the EASD meeting later that month. At this article’s 19 September review date, those announced presentations had not yet taken place.Lilly — Forthcoming EASD 2026 presentations, 15 September 2026 (opens in a new tab)
These records mean that describing the programme as only having reached phase 2 would be out of date. They are sponsor communications, however, and are labelled here as such rather than presented as independently assessed full trial reports.
This guide does not reproduce the new topline effect estimates or infer an approval decision from a planned submission. Detailed interpretation belongs with the complete relevant results and their stated analyses.
Keep a clear boundary around research-catalogue claims
For literature matching, the name and complete modified structure identify the intended research molecule. They do not connect a current vial to the sponsor’s manufacturing, formulation or clinical-trial supply.
| Record | What it can contribute |
|---|---|
| Discovery paper | Molecular and receptor research context |
| Clinical trial report | Outcomes for the studied preparation and participants |
| Supplier documentation | Information about the supplied research material |
A certificate cannot inherit clinical outcomes from a journal paper, and a journal paper cannot verify the contents of an unrelated vial. Keeping these records separate allows the clinical research to be described accurately without turning it into a product endorsement.
Future updates should add the full report identifier, population and measured endpoint. That keeps this reference useful as the research record develops while preserving the distinction between an investigated molecule and a supplied research material.
Sources and further detail
- Urva and colleagues — LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes (opens in a new tab)
Original 2022 indexed publisher description and PubMed metadata checked. Used only for the 39-residue single-peptide and C20-conjugate identity, not an administration regimen.
- Coskun and colleagues — LY3437943: From discovery to clinical proof of concept (opens in a new tab)
Original 2022 abstract and authors checked. Brief receptor-target description; direct Cell page access failed. No detailed receptor potency ratios or animal procedures reproduced.
- Jastreboff and colleagues — Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (opens in a new tab)
Original 2023 indexed abstract, endpoint description, participant results and safety section checked. Short balanced summary only, with no clinical-use instructions.
- Lilly — Retatrutide results in two additional phase 3 obesity trials, 23 July 2026 (opens in a new tab)
Primary sponsor announcement checked for TRIUMPH-2/3, date and investigational wording. Labelled as topline reporting; detailed results not independently assessed here.
- Lilly — Forthcoming EASD 2026 presentations, 15 September 2026 (opens in a new tab)
Primary dated sponsor announcement checked for the 28 September–2 October meeting. Forthcoming events are not described as already presented at the 19 September review date.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.